Welcome!

News Feed Item

Biologicals in Oncology Drug Pipeline Update 2013

NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biologicals in Oncology Drug Pipeline Update 2013

http://www.reportlinker.com/p0379872/Biologicals-in-Oncology-Drug-Pipeli...

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.

There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.Drug Pipeline Update at a Glance

InvestigatorsIncludes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & SynonymsLists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

Marketed# 141

Registered# 2

Pre-registration# 9

Phase III# 109

Phase II# 371

Phase I# 405

Preclinical# 935

No Data# 12

Suspended# 24

Ceased# 889

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

Included biological drugs are also in development for 337 other indications, where of 115 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

TargetsMutationsAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures

The identity of available biological structures on 349 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4087 structures available today among drug targets.

Identified drugs are linked to more than 604 different targets, divided into 82 classifications of molecular function:- Acid phosphatase activity- Antigen binding- ATPase activity- Auxiliary transport protein activity- B cell receptor activity- Binding- Carboxy-lyase activity- Carboxypeptidase activity- Catalytic activity- Cell adhesion molecule activity- Chaperone activity- Chemokine activity- Cofactor binding- Complement activity- Cysteine-type peptidase activity- Cytokine activity- Cytoskeletal protein binding- Deaminase activity- Defense/immunity protein activity- DNA binding- DNA repair protein- DNA topoisomerase activity- DNA-directed DNA polymerase activity- DNA-directed RNA polymerase activity- DNA-methyltransferase activity- Extracellular ligand-gated ion channel activity- Extracellular matrix structural constituent- Fucosyltransferase activity- G-protein coupled receptor activity- Growth factor activity- Growth factor binding- GTPase activator activity- GTPase activity- Guanylate cyclase activity- Heat shock protein activity- Hormone activity- Hydrolase activity- Intracellular ligand-gated ion channel activity- Isomerase activity- Kinase activity- Kinase binding- Kinase regulator activity- Ligand-dependent nuclear receptor activity- Ligase activity- Lipid kinase activity- Lipid phosphatase activity- Metallopeptidase activity- MHC class I receptor activity- Molecular function unknown- Motor activity- Oxidoreductase activity- Peptidase activity- Peptide hormone- Peroxidase activity- Protease inhibitor activity- Protein binding- Protein serine/threonine kinase activity- Protein threonine/tyrosine kinase activity- Protein tyrosine/serine/threonine phosphatase activity- Protein-tyrosine kinase activity- Receptor activity- Receptor binding- Receptor signaling complex scaffold activity- Receptor signaling protein serine/threonine kinase activity- Receptor signaling protein tyrosine phosphatase activity- RNA binding- RNA-directed DNA polymerase activity- Serine-type peptidase activity- Signal transducer activity- Structural constituent of cytoskeleton- Structural molecule activity- Superoxide dismutase activity- T cell receptor activity- Transcription factor activity- Transcription regulator activity- Transferase activity- Translation regulator activity- Transmembrane receptor activity- Transmembrane receptor protein tyrosine kinase activity- Transporter activity- Ubiquitin-specific protease activity- Unclassified

Sub-Cellular Localization

Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:

- Apical membrane

- Cell junction

- Cell surface

- Centrosome

- Clathrin-coated vesicle

- Cytoplasm

- Cytoplasmic vesicle

- Cytoskeleton

- Cytosol

- Early endosome

- Endoplasmic reticulum

- Endosome

- Extracellular

- Extracellular matrix

- Golgi apparatus

- Golgi membrane

- Immunological synapse

- Integral to membrane

- Kinetochore

- Late endosome

- Lysosome

- Membrane fraction

- Microtubule

- Mitochondrial matrix

- Mitochondrial membrane

- Mitochondrion

- Nucleolus

- Nucleus

- Perinuclear region

- Perinuclear vesicle

- Peroxisomal matrix

- Plasma membrane

- Sarcoplasmic reticulum

- Secreted

- Secretory granule

- Secretory vesicle

- Soluble fraction

- Vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile

Direct links are provided from inside the application to 716 protein expression profiles of 470 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:

- 48 different normal tissue types

- 20 different types of cancer

- 47 cell lines

- 12 samples of primary blood cells

Pathway ReferalsIdentified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.- BioCarta# 265 Pathways- KEGG# 194 Pathways- NCI-Nature# 251 Pathways- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

MechanismIn total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

CompoundIdentified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms

Principal Company & Partners

Presentation of principal company and partners

Target and Molecular Function of TargetDescribed target(s) is/are presented with:Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function

Target Localization

Described target(s) is/are presented with primary and alternate localizations.

Target Expression Profiles

Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:

48 different normal tissue types

20 different types of cancer

47 cell lines

12 samples of primary blood cells

MutationAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.

Biological Structures

The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted PathwaysDescribed target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism

Drug mechanism of action

Developmental ProjectsSummary field of developmental projects for the drug, including indication, developmental stage and status.Example:Cancer, myeloma – Phase II Clinical Trial – ActiveCancer, prostate – Phase III Clinical Trial – Ceased

Drug Description

Short introduction to drug

Compound DataCompound type, Chemical name, CAS Number and molecular weight

Patent Data

Available patent information related to the drug is presented here.

Fillings and ApprovalsApprovals and submissionsAnalyst comments

Deals & Licensing

Collaborations and deals

Availability for licensing

Phase IV DataAvailable Phase IV development data, developmental history and scientific data.

Phase III Data

Available Phase III development data, developmental history and scientific data.

Phase II DataAvailable Phase II development data, developmental history and scientific data.

Phase I Data

Available Phase I development data, developmental history and scientific data.

Phase 0 DataAvailable Phase 0 development data, developmental history and scientific data.

Preclinical Data

Available preclinical development data, developmental history and scientific data.

Discovery DataAvailable discovery development data, developmental history and scientific data.

Application Features

Search, Find and Filter Panel with Initial Result Presentation

With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.

Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.

Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources

- Drug data is linked to search engines like Google and PubMed

- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.

- Direct links to company web pages of companies

Dynamic Report GeneratorOur dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

Click here for a short video (6m12s) showing a typical drug profile

System Requirements- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)- Browser Application (Internet Explorer)- Internet access (to access related internet resources)

To order this report:Drug_Discovery_and_Development Industry: Biologicals in Oncology Drug Pipeline Update 2013

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
The Internet giants are fully embracing AI. All the services they offer to their customers are aimed at drawing a map of the world with the data they get. The AIs from these companies are used to build disruptive approaches that cannot be used by established enterprises, which are threatened by these disruptions. However, most leaders underestimate the effect this will have on their businesses. In his session at 21st Cloud Expo, Rene Buest, Director Market Research & Technology Evangelism at Ara...
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Tintri focuses on the Ops side of the DevOps, which basically is pushing more and more of the accessibility of the infrastructure to the developers and trying to get behind the scenes," explained Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...